Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Dysken

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of the American Geriatrics Society|May 1, 1995
Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary studyJ R Mach, M W Dysken, M Kuskowski, et al.
International Psychogeriatrics|January 1, 1991
Seasonal distribution of births in Alzheimer's diseaseM W Dysken, M Kuskowski, S S Skare, et al.
Psychopharmacology|January 1, 1981
Fluphenazine pharmacokinetics and therapeutic responseM W Dysken, J I Javaid, S S Chang, et al.
Journal of Clinical Psychopharmacology|June 1, 1992
Haloperidol and reduced haloperidol in saliva and bloodM W Dysken, S B Johnson, L Holden, et al.
Biological Psychiatry|April 1, 1993
Intrasubject reproducibility of growth hormone-releasing hormone-stimulated growth hormone in older women, older men, and younger menM W Dysken, S S Skare, M S Burke, et al.
Advances in Biochemical Psychopharmacology|January 1, 1980
Plasma levels and therapeutic efficacy of fluphenazine hydrochloride and decanoateM W Dysken, S S Chang, C Schaffer, et al.
Journal of Clinical Psychopharmacology|April 1, 1992
Haloperidol decanoate pharmacokinetics in red blood cells and plasmaM W Dysken, S W Kim, G Vatassery, et al.
Brain Research|July 9, 1993
Blunting of the neurotensin mRNA response to haloperidol in the striatum of aging rats: possible relationship to decline in dopamine D2 receptor expressionD J Dobie, K M Merchant, M W Hamblin, et al.
The American Journal of Psychiatry|February 1, 1990
Tourette's disorder in a set of reared-apart triplets: genetic and environmental influencesN L Segal, M W Dysken, T J Bouchard, et al.
Psychopharmacology|January 1, 1985
Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophreniaS S Chang, J I Javaid, M W Dysken, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of the American Geriatrics Society|May 1, 1995
Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary studyJ R Mach, M W Dysken, M Kuskowski, et al.
International Psychogeriatrics|January 1, 1991
Seasonal distribution of births in Alzheimer's diseaseM W Dysken, M Kuskowski, S S Skare, et al.
Psychopharmacology|January 1, 1981
Fluphenazine pharmacokinetics and therapeutic responseM W Dysken, J I Javaid, S S Chang, et al.
Journal of Clinical Psychopharmacology|June 1, 1992
Haloperidol and reduced haloperidol in saliva and bloodM W Dysken, S B Johnson, L Holden, et al.
Biological Psychiatry|April 1, 1993
Intrasubject reproducibility of growth hormone-releasing hormone-stimulated growth hormone in older women, older men, and younger menM W Dysken, S S Skare, M S Burke, et al.
Advances in Biochemical Psychopharmacology|January 1, 1980
Plasma levels and therapeutic efficacy of fluphenazine hydrochloride and decanoateM W Dysken, S S Chang, C Schaffer, et al.
Journal of Clinical Psychopharmacology|April 1, 1992
Haloperidol decanoate pharmacokinetics in red blood cells and plasmaM W Dysken, S W Kim, G Vatassery, et al.
Brain Research|July 9, 1993
Blunting of the neurotensin mRNA response to haloperidol in the striatum of aging rats: possible relationship to decline in dopamine D2 receptor expressionD J Dobie, K M Merchant, M W Hamblin, et al.
The American Journal of Psychiatry|February 1, 1990
Tourette's disorder in a set of reared-apart triplets: genetic and environmental influencesN L Segal, M W Dysken, T J Bouchard, et al.
Psychopharmacology|January 1, 1985
Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophreniaS S Chang, J I Javaid, M W Dysken, et al.
Pageof 7